Antitachycardia pacing for reduction of implantable cardioverter-defibrillator shocks

Daniel J Cantillon; Bruce L Wilkoff

doi:10.1016/j.hrthm.2015.02.024

Antitachycardia pacing for reduction of implantable cardioverter-defibrillator shocks

Heart Rhythm. 2015 Jun;12(6):1370-5. doi: 10.1016/j.hrthm.2015.02.024. Epub 2015 Feb 20.

Authors

Daniel J Cantillon¹, Bruce L Wilkoff²

Affiliations

¹ Cleveland Clinic, Heart and Vascular Institute, Cardiac Electrophysiology and Pacing, Cleveland, Ohio. Electronic address: [email protected].
² Cleveland Clinic, Heart and Vascular Institute, Cardiac Electrophysiology and Pacing, Cleveland, Ohio.

PMID: 25708880
DOI: 10.1016/j.hrthm.2015.02.024

Abstract

Antitachycardia pacing (ATP) strategies represent safe, effective, and painless therapy for ventricular tachyarrhythmias, with a large body of clinical evidence supporting their routine use in both primary and secondary implantable cardioverter-defibrillator recipients. This article details the evidence supporting the use of standardized and validated ATP strategies for primary prevention patients and the conceptual framework to design effective ATP strategy for secondary prevention patients.

Keywords: Antitachycardia pacing; Implantable cardioverter-defibrillator; Sudden cardiac death.

MeSH terms

Cardiac Pacing, Artificial*
Defibrillators, Implantable / adverse effects*
Humans
Tachycardia / therapy*